CIC
TRDA icon

Cornercap Investment Counsel’s Entrada Therapeutics TRDA Stock Holding History

Cornercap Investment Counsel’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,014
Closed -$185K – 634
2024
Q2 		$185K Sell
13,014
-129
-1% -$1.83K 0.03% 545
2024
Q1 		$186K Buy
+13,143
New +$186K 0.03% 572
2023
Q4 		– Sell
-13,977
Closed -$221K – 650
2023
Q3 		$221K Buy
+13,977
New +$220K 0.04% 484

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Cornercap Investment Counsel's TRDA Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Entrada Therapeutics (TRDA) in Q3 2024, closing a stake of 13,014 shares — an estimated $185K sold.

Cornercap Investment Counsel first reported a position in TRDA in Q3 2023 and held it in 3 quarters. The position peaked at $221K in Q3 2023. 97 funds tracked by Wall St. Rank hold TRDA as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Entrada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 13,014 Entrada Therapeutics shares in Q3 2024, an estimated $185K.
  • Cornercap Investment Counsel first reported a position in Entrada Therapeutics in Q3 2023 and held it in 3 quarters.
  • Cornercap Investment Counsel's Entrada Therapeutics position peaked at $221K in Q3 2023.
  • 97 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.